Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18749771 | COMPOSITIONS AND METHODS FOR DETECTING PANCREATIC CANCER | June 2024 | June 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18405910 | BINDING MOLECULES | January 2024 | June 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18501589 | Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses Thereof | November 2023 | January 2025 | Abandon | 15 | 1 | 1 | Yes | No |
| 18381344 | INTRACELLULAR DELIVERY COMPOSITIONS | October 2023 | April 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18060455 | USE OF TENASCIN-C AS AN EXTRACELLULAR MARKER OF TUMOR-DERIVED MICROPARTICLES | November 2022 | June 2025 | Allow | 30 | 3 | 0 | Yes | No |
| 17895295 | ANTI-PSMA ANTIBODIES AND USES THEREOF | August 2022 | February 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 17819483 | ANTI-LAMBDA MYELOMA ANTRIGEN (LMA) BINDING PROTEINS TO TREAT LMA-EXPRESSING CANCER AND AUTOIMMUNE DISORDERS | August 2022 | April 2025 | Allow | 33 | 0 | 1 | No | No |
| 17876899 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | July 2022 | October 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17868368 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | July 2022 | September 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17851277 | RECOMBINANT ANTIBODY AND USES THEREOF | June 2022 | September 2023 | Allow | 14 | 0 | 1 | Yes | No |
| 17851947 | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF | June 2022 | February 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 17845916 | CD200 INHIBITORS AND METHODS OF USE THEREOF | June 2022 | February 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 17725623 | HUMANIZED ANTl-CD19 ANTIBODY AND USE THEREOF WITH CHIMERIC ANTIGEN RECEPTOR | April 2022 | January 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 17681268 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | February 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17652471 | METHOD OF SELECTION FOR TREATMENT OF SUBJECTS AT RISK OF INVASIVE BREAST CANCER | February 2022 | September 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17581085 | TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY | January 2022 | June 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17573657 | CORONAVIRUS-BINDING MOLECULES AND METHODS OF USE THEREOF | January 2022 | January 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17570933 | THERAPEUTIC AGENTS AND USES THEREOF | January 2022 | April 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17565994 | THERAPEUTIC MUSK ANTIBODIES | December 2021 | September 2022 | Allow | 9 | 0 | 1 | Yes | No |
| 17554329 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | December 2021 | February 2025 | Allow | 38 | 2 | 1 | No | No |
| 17553953 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | December 2021 | March 2022 | Allow | 3 | 0 | 0 | No | No |
| 17554283 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | December 2021 | April 2025 | Allow | 39 | 2 | 1 | No | No |
| 17552862 | METHODS AND COMPOSITION FOR A BINDING MOLECULE TARGETING CANCER CELLS EXPRESSING SSX2 PEPTIDE 41-49 IN HLA-A*0201 CONTEXT | December 2021 | October 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17547315 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | December 2021 | February 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17546983 | ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND USES THEREOF | December 2021 | August 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17541560 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | December 2021 | March 2025 | Allow | 39 | 2 | 1 | No | No |
| 17541537 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | December 2021 | November 2022 | Allow | 11 | 0 | 0 | No | No |
| 17541555 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | December 2021 | January 2025 | Allow | 37 | 2 | 1 | No | No |
| 17534916 | ANTI-TIGIT ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS | November 2021 | April 2024 | Allow | 29 | 0 | 1 | Yes | No |
| 17533784 | FUSION PROTEINS TARGETING TUMOUR ASSOCIATED MACROPHAGES FOR TREATING CANCER | November 2021 | November 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17529322 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | November 2021 | November 2024 | Allow | 36 | 2 | 1 | No | No |
| 17530072 | ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIES | November 2021 | November 2024 | Allow | 36 | 0 | 1 | Yes | No |
| 17517934 | PLECTIN-1 BINDING ANTIBODIES AND USES THEREOF | November 2021 | March 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17514903 | COMPOSITIONS FOR TARGETING SARS-COV-2 SPIKE PROTEIN RECEPTOR BINDING DOMAIN | October 2021 | February 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17606246 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | October 2021 | August 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17451607 | BREAST AND OVARIAN CANCER VACCINES | October 2021 | April 2024 | Allow | 30 | 0 | 1 | Yes | No |
| 17502686 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | October 2021 | January 2022 | Allow | 3 | 0 | 0 | No | No |
| 17442720 | GENETICALLY ENGINEERED DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | September 2021 | December 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17478497 | LAG-3 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | September 2021 | January 2024 | Allow | 28 | 0 | 1 | Yes | No |
| 17474894 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | September 2021 | October 2024 | Allow | 37 | 2 | 1 | No | No |
| 17471754 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | September 2021 | March 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17470778 | T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES | September 2021 | May 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17459133 | CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17405650 | COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF | August 2021 | March 2022 | Allow | 7 | 0 | 0 | Yes | No |
| 17405246 | COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF | August 2021 | November 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17402262 | COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET | August 2021 | January 2024 | Allow | 29 | 1 | 0 | No | No |
| 17397559 | ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF | August 2021 | June 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17394556 | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES | August 2021 | April 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17392075 | IL-7R-alpha SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA | August 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17310296 | MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO CCSP-2 AND USE THEREOF | July 2021 | October 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17384894 | METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS | July 2021 | October 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17384602 | TUMOR CELL-DERIVED MICROVESICLES | July 2021 | March 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17372961 | HUMANIZED ANTI-AXL ANTIBODIES | July 2021 | July 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17369169 | SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST CTLA4 | July 2021 | November 2023 | Allow | 28 | 0 | 1 | Yes | No |
| 17366958 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | July 2021 | October 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17366885 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | July 2021 | April 2024 | Allow | 34 | 2 | 1 | No | No |
| 17364531 | ESOPHAGEAL CANCER MARKER AND USE THEREOF | June 2021 | March 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17304823 | BREAST AND OVARIAN CANCER VACCINES | June 2021 | September 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17418475 | FUSION PROTEIN OF ANTIBODY THAT RECOGNIZES CANCER CELLS AND MUTANT STREPTAVIDIN | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17345033 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC MACULAR EDEMA | June 2021 | April 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17340102 | CONDITIONAL INTERNALIZATION OF PEGYLATED AGENTS BY PRETARGETING BI-SPECIFIC PEG-BINDING ANTIBODIES FOR DIAGNOSIS AND THERAPY | June 2021 | October 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17331344 | ANTI-HUMAN LAG-3 ANTIBODIES AND THEIR USE IN IMMUNOHISTOCHEMISTRY (IHC) | May 2021 | January 2023 | Allow | 20 | 0 | 1 | Yes | No |
| 17328597 | ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER | May 2021 | April 2022 | Allow | 10 | 0 | 0 | Yes | No |
| 17327193 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | May 2021 | May 2024 | Allow | 36 | 2 | 1 | No | No |
| 17294582 | ETANERCEPT VARIANTS WITH IMPROVED THERAPEUTICAL EFFECT | May 2021 | December 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17314650 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | May 2021 | October 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17314668 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | May 2021 | February 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17314688 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | May 2021 | October 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17308691 | PROTEINS BINDING NKG2D, CD16 AND CLEC12A | May 2021 | July 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17289810 | DOSING REGIMEN OF ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER | April 2021 | June 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17229592 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | April 2021 | June 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17284617 | TREATMENT AND PREVENTION OF MALARIA | April 2021 | April 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17226153 | COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF | April 2021 | June 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17205634 | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor | March 2021 | June 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17174019 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | February 2021 | March 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17087765 | ANTIBODIES TARGETING QUIESCIN SULFHYDRYL OXIDASE (QSOX1) AND USES OF SAME | February 2021 | November 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17165833 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | February 2021 | July 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17158474 | ANTI-HUMAN 4-1BB ANTIBODIES AND USES THEREOF | January 2021 | August 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17150617 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | January 2021 | April 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17149381 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | January 2021 | March 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17149397 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | January 2021 | August 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17149241 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | January 2021 | July 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17144853 | ANTIBODIES SPECIFIC TO TROPHOBLAST ANTIGEN 2 (TROP2) | January 2021 | October 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17131713 | HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2 | December 2020 | May 2023 | Allow | 28 | 0 | 1 | Yes | No |
| 17129096 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | December 2020 | December 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17123865 | ANTI-RSPO3 ANTIBODIES AND METHODS OF USE | December 2020 | October 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17121541 | Anti-Transglutaminase 2 Antibodies | December 2020 | March 2023 | Allow | 27 | 0 | 1 | Yes | No |
| 17116845 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | December 2020 | February 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17114193 | CD200 INHIBITORS AND METHODS OF USE THEREOF | December 2020 | June 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17103318 | Reagents and Methods for Monitoring Breast Cancer Therapy | November 2020 | June 2024 | Abandon | 43 | 1 | 1 | No | No |
| 16950645 | METHODS FOR INHIBITING ANGIOGENESIS IN A SUBJECT IN NEED THEREOF | November 2020 | January 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17056384 | METHODS OF ISOLATING ALLERGEN-SPECIFIC ANTIBODIES FROM HUMANS AND USES THEREOF | November 2020 | May 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17055561 | COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF | November 2020 | May 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17096750 | ANTI-CANCER FUSION POLYPEPTIDE | November 2020 | June 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17094495 | USE OF MARIZOMIB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS | November 2020 | January 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17052960 | ANTIBODIES SPECIFIC TO HUMAN NECTIN4 | November 2020 | April 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17086817 | METHOD FOR IMPROVED DIAGNOSIS OF DYSPLASIAS | November 2020 | March 2023 | Abandon | 29 | 3 | 0 | Yes | Yes |
| 17048490 | REPROGRAMMING CD4 T CELLS INTO CYTOTOXIC CD8 CELLS BY FORCED EXPRESSION OF CD8aB AND CLASS 1 RESTRICTED T CELL RECEPTORS | October 2020 | March 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17072612 | COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION | October 2020 | March 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17070623 | ANTIBODY MOLECULE FOR HUMAN GM-CSF RECEPTOR ALPHA | October 2020 | May 2024 | Abandon | 43 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YAO, LEI.
With a 35.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner YAO, LEI works in Art Unit 1642 and has examined 1,137 patent applications in our dataset. With an allowance rate of 56.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner YAO, LEI's allowance rate of 56.2% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by YAO, LEI receive 1.70 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by YAO, LEI is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +70.1% benefit to allowance rate for applications examined by YAO, LEI. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.1% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 32.9% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 76.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.8% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 61.2% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 5.9% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.